重新评估英国人群中诺如病毒传播的总负担
基于英国第二次感染性肠道疾病研究(IID2),采用较诊断实验室更严格的循环阈值(ct<30)定义临床显著诺如病毒,估计发病率为47/1000人年。随着诺如病毒候选疫苗可能出现,准确估计总感染负担有助于指导疫苗接种政策。
要点
- 采用较宽松但具诊断相关性的阈值,诺如病毒感染负担增加约26%,达59/1000人年(95%CI 52.32-64.98)。
研究设计与样本
- 基于英国第二次感染性肠道疾病研究(IID2)的再评估,IID2原采用循环阈值(ct)<30定义临床显著诺如病毒。
主要发现
- 采用较宽松但具诊断相关性的阈值后,诺如病毒感染的人群负担估计增加约26%,达59/1000人年(95%CI 52.32-64.98)。
关键数值与推荐
- IID2定义临床显著诺如病毒采用ct<30,较诊断实验室所用阈值更严格。
- 采用较宽松但具诊断相关性的阈值后,估计值为59/1000人年(95%CI 52.32-64.98)。
临床怎么用
- 随着诺如病毒候选疫苗可能出现,准确估计诺如病毒感染总负担及症状性疾病负担有助于指导疫苗接种政策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The second Infectious Intestinal Diseases study (IID2) estimated the incidence of norovirus in the UK at 47/1000 population (three million cases annually). Clinically significant norovirus was defined using a cycle threshold (ct) value of <30; a more stringent cut-off than used in diagnostic laboratories. The low infectious dose of norovirus means asymptomatic individuals potentially contribute to ongoing transmission. Using a less stringent but diagnostically relevant threshold increases the estimation of the population burden of norovirus infection by around 26% to 59/1000 person years (95% CI 52.32-64.98), equating to 3.7 million norovirus infections annually (3.3-4.1 million). With possible vaccines on the horizon for norovirus, having a good estimate of the total burden of norovirus infection, as well as symptomatic disease will be useful in helping to guide vaccination policy when candidate vaccines become available.
引用
- Harris JP, Iturriza-Gomara M, O'Brien SJ, et al. Re-assessing the total burden of norovirus circulating in the United Kingdom population. Vaccine. 2017. PMID: 28094075. doi:10.1016/j.vaccine.2017.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。